NCT03263130 Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
| NCT ID | NCT03263130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gelb, Arthur F., M.D. |
| Condition | COPD, Emphysema, Asthma COPD Overlap |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2017-01-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2017-01-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).
Eligibility Criteria
Inclusion Criteria: * asthma- copd overlap * emphysema in smokers with smoking history \> 15 pack years * COPD/ bronchitis and bronchiectasis in smokers with smoking history * \>15 pack years Exclusion Criteria:other pulmonary or systemic diagnosis * non smokers * any other pulmonary diagnosis * pulmonary fibrosis
Contact & Investigator
Arthur F Gelb, MD
PRINCIPAL INVESTIGATOR
Clin Prof Geffen School of Medicine at UCLA Medical Center
Frequently Asked Questions
Who can join the NCT03263130 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying COPD, Emphysema, Asthma COPD Overlap. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03263130 currently recruiting?
Yes, NCT03263130 is actively recruiting participants. Contact the research team at afgelb@msn.com for enrollment information.
Where is the NCT03263130 trial being conducted?
This trial is being conducted at Lakewood, United States, Lakewood, United States.
Who is sponsoring the NCT03263130 clinical trial?
NCT03263130 is sponsored by Gelb, Arthur F., M.D.. The principal investigator is Arthur F Gelb, MD at Clin Prof Geffen School of Medicine at UCLA Medical Center. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.